| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/22/2003 | CA2243274C Male contraceptive implant |
| 07/22/2003 | CA2189328C Tocopherol compositions for delivery of biologically active agents |
| 07/22/2003 | CA2117769C Liposome composition |
| 07/22/2003 | CA2102185C Process for the preparation of nanoparticles |
| 07/21/2003 | CA2416791A1 A receptor-ligand pairing for immune response |
| 07/21/2003 | CA2368656A1 Receptor-ligand pairing for anti-inflammatory response |
| 07/17/2003 | WO2003057906A1 A new vector for genetically modifying non-human animals |
| 07/17/2003 | WO2003057852A2 Purification and characterization of hla proteins |
| 07/17/2003 | WO2003057838A2 Antibodies against the muc18 antigen |
| 07/17/2003 | WO2003057837A2 Methods for using anti-muc18 antibodies |
| 07/17/2003 | WO2003057829A2 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | WO2003057716A2 Dendritic encapsulation of active agents |
| 07/17/2003 | WO2003057650A2 Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
| 07/17/2003 | WO2003057359A2 Microparticles and methods for their production |
| 07/17/2003 | WO2003057278A2 Drug delivery system for sustained delivery of glipizide |
| 07/17/2003 | WO2003057226A1 Use of phospholipids in peritoneal dialysis |
| 07/17/2003 | WO2003057208A1 Taxane based compositions and methods of use |
| 07/17/2003 | WO2003057199A1 Adhesive and binding agent for dermal or transdermal treatment systems |
| 07/17/2003 | WO2003057197A1 Novel pharmaceutical dosage forms and method for producing same |
| 07/17/2003 | WO2003057194A1 Sterile filtered nanoparticule formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
| 07/17/2003 | WO2003057192A1 Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier |
| 07/17/2003 | WO2003057179A2 Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| 07/17/2003 | WO2003057175A2 Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor |
| 07/17/2003 | WO2003057170A2 Oral insulin therapy |
| 07/17/2003 | WO2003057163A2 Methods for preparing immunoconjugates |
| 07/17/2003 | WO2003057160A2 Compositions and methods for the diagnosis and treatment of tumor |
| 07/17/2003 | WO2003057155A2 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 07/17/2003 | WO2003057153A2 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 07/17/2003 | WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | WO2003057136A2 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| 07/17/2003 | WO2003057135A2 Aqueous compositions containing metronidazole |
| 07/17/2003 | WO2003057133A2 Herbal composition for treating various disorders including psoriasis, a process for preparation thereof and method for treatment of such disorders |
| 07/17/2003 | WO2003057006A2 Use of antibodies against the muc18 antigen |
| 07/17/2003 | WO2003056931A1 Chewing gum composition for eliminating nicotine |
| 07/17/2003 | WO2003040398A3 Proteins stabilized with polysaccharide gums |
| 07/17/2003 | WO2003020325A3 Methods for sterilizing preparations containing albumin |
| 07/17/2003 | WO2003000184A3 Truncated apolipoprotein b-containing lipoprotein particles for delivery of components to tissues or cells |
| 07/17/2003 | WO2002098465A3 Cell penetrating therapeutic agents |
| 07/17/2003 | WO2002086074A3 Compositions for delivery of compounds to cells and methods of use |
| 07/17/2003 | WO2002083928A3 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 07/17/2003 | WO2002055693A3 Method for inhibiting the expression of a target gene |
| 07/17/2003 | WO2002055020A3 Topical testosterone formulations and associated methods |
| 07/17/2003 | WO2002039947A3 Carrier vectors through an epithelium with tight junctions |
| 07/17/2003 | WO2002000171A3 Composition for delivery of hematopoietic growth factor |
| 07/17/2003 | WO1999044581A3 Pharmaceutical composition of topiramate |
| 07/17/2003 | US20030135238 In situ bonds |
| 07/17/2003 | US20030135113 Method of drug delivery to interstitial regions of the myocardium |
| 07/17/2003 | US20030135029 Tumour necrosis factor binding ligands |
| 07/17/2003 | US20030134908 Pharmaceutical compositions |
| 07/17/2003 | US20030134906 Modified release pharmaceutical composition containing bupropion HCI as active substance |
| 07/17/2003 | US20030134903 Substituted aminoalkanoate or substituted aminoalkyl alkanoate as a penetration enhancer a shear-thinning polysaccharide, a lipophilic compound, and an acidic buffer system. |
| 07/17/2003 | US20030134887 Orally administering celecoxib formulated in such a way as to provide a blood plasma concentration profile of celecoxib of 250 ng/ml in not later than 30 minutes |
| 07/17/2003 | US20030134878 Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith |
| 07/17/2003 | US20030134826 Cell surface binding group or a cell recognising group, and also by a bio-active group, the bio- active group attached to a carbonyl of the cross-linker by an acid labile bond. Examples of suitable bio-active groups including |
| 07/17/2003 | US20030134824 The invention provides beta -cyclodextrin dimers and phthalocyanines which can be used in photodynamic therapy of cancer. |
| 07/17/2003 | US20030134819 Recombinant bacterial cells for delivery of PNP to tumor cells |
| 07/17/2003 | US20030134815 Adenovirus mediated transfer of genes to the gastrointestinal tract. In particular, the present invention relates to a method of recombinant, replication-deficient adenovirus mediated transfer of therapuetic genes to the |
| 07/17/2003 | US20030134813 Method for introducing molecules in cells by disrupting endosomal and lysosomal membranes using photodynamic treatment, without killing the majority of the cells by the photodynamic treatment. More particularly, this invention |
| 07/17/2003 | US20030134811 Methods and compositions comprising hydroxyapatite useful for the administration of therapeutic agents |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid |
| 07/17/2003 | US20030134793 Water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly- aspartic acid or -lysine. Methods of using the compositions for treatment of |
| 07/17/2003 | US20030134789 Compositions and methods for protecting tissues and cells from damage, and for repairing damaged tissues |
| 07/17/2003 | US20030134787 Engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response in a subject in |
| 07/17/2003 | US20030134782 Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system, comprises a unique peptide having 31 amino acids and unique peptide having 21 amino acids and connected with an oligo-nucleotide through |
| 07/17/2003 | US20030134778 Pharmaceutical composition comprising factor VIII and neutral liposomes |
| 07/17/2003 | US20030134424 For implanting/transfecting monodispersed silicon particles joined to DNA into target tissue, cell or the blood stream |
| 07/17/2003 | US20030134027 Comprises pectin, alginate, calcium, and fiber; dietetics |
| 07/17/2003 | US20030133991 Composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in carrier, which, when applied to open wound, modulates activity of MMP-2 and/or MMP- 9 in wound; ulcer treatment |
| 07/17/2003 | US20030133989 Skin care products containing whole egg |
| 07/17/2003 | US20030133988 Immunomodulation accomplished by administration of immunomodulatory polynucleotide/microcarrier complexes comprising 3-6 mer immunomodulatory oligonucleotides |
| 07/17/2003 | US20030133987 Preparing emulsion comprising water and templating agent, preparing drug mixture, combining template emulsion with drug-containing mixture to form template emulsion loaded with drug particles; faster dissolution, bioavailability |
| 07/17/2003 | US20030133986 Compositions for stabilizing poly (carboxylic acids) |
| 07/17/2003 | US20030133985 Controlled release oral dosage forms; data obtained using disintegration test such as the established USP Disintegration Test, rather than the results obtained using a standard USP Dissolution Test, as is conventionally done |
| 07/17/2003 | US20030133984 Comprising poorly water soluble drug, solubilizing component, and surfactant which is semisolid or solid; drug may e.g. be a cyclosporin or a macrolide; immunosuppressants |
| 07/17/2003 | US20030133983 Comprises core and enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a derivative thereof; treatment of ulcerative colitis and Crohn's disease |
| 07/17/2003 | US20030133982 Suitable for administration of a wide range of therapeutically active medicaments, especially those that are water-soluble; ethylcellulose core, active agent, hydrophobic polymer coating |
| 07/17/2003 | US20030133981 Extended release formulations of erythromycin derivatives |
| 07/17/2003 | US20030133980 Biocompatible polymer blends and uses thereof |
| 07/17/2003 | US20030133979 Device for the sustained release of aggregation-stabilized, biologically active agent |
| 07/17/2003 | US20030133976 Effervescent drug delivery system for oral administration |
| 07/17/2003 | US20030133975 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
| 07/17/2003 | US20030133973 Vesicle-forming lipid and a vesicle-forming lipid derivatized with a hydrophilic polymer |
| 07/17/2003 | US20030133972 Macromolecules of 3-(4-(2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)-ethyloxy)-benzoylamino)-2(S)-benzene-sulfonyl -aminopropionic acid moiety |
| 07/17/2003 | US20030133970 Occlusive transdermal therapeutic system with a non-occlusive backing layer |
| 07/17/2003 | US20030133964 Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/17/2003 | US20030133959 Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions |
| 07/17/2003 | US20030133955 Methods and compositions useful for administration of chemotherapeutic agents |
| 07/17/2003 | US20030133954 Medical compositions for intravesical treatment of bladder cancer |
| 07/17/2003 | US20030133953 Complexing a biologically active agent with a perturbant to reversibly transform and exposing a membrane or bilayer to the supramolecular complex |
| 07/17/2003 | US20030133950 Inducing a desired T helper lymphocyte regulated immune response by delivering an immunogen to a preselected region of the gastrointestinal tract of a patient |
| 07/17/2003 | US20030133940 Medicaments for chemotherapeutic treatment of disease |
| 07/17/2003 | US20030133938 Antibody-avidin fusion proteins as cytotoxic drugs |
| 07/17/2003 | US20030133937 Incubating the biological preparation with a saccharide, a glycoconjugate or an antibody that inhibits the binding of malignant cells expressing sialyl Lea or di-sialyl Lea, to endothelial cells expressing a LEC-CAM (selectin) |
| 07/17/2003 | US20030133934 Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method |
| 07/17/2003 | US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen. |
| 07/17/2003 | US20030133927 Conjugates useful in the treatment of prostate cancer |
| 07/17/2003 | US20030133905 Composition for treating contact lenses in the eye |
| 07/17/2003 | US20030133902 Method of making phosphate-binding polymers for oral administration |
| 07/17/2003 | US20030133896 Comprises one or more hydrophobically amine-modified polylactam/polypeptide copolymers of glutamic acid; also polar waxes; skin-friendly pH of 5.5; high/low temperature stability; brightness; pleasent feel; biodegradable |